December 2021 "Early-stage studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and was first identified in South Africa in early November, and an existing treatment has already shown positive shots against the variant, the monoclonal antibody sotrovimab from Vir and partner GlaxoSmithKline PLC posted Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID

Research over the past years has provided a substantial body of evidence demonstrating that platelets also participate in host innate immunity. In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than ever, as a majority of COVID-19 patients display thrombi in the lung capillaries and other vascular

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine truncations, frame shifts and point mutations in the chemokine receptor CXCR4 have been identified in WHIM syndrome Here, we report on a new WHIM syndrome mutation that results in a frame shift within the codon for Ser339 S339fs5) and compare the properties of S339fs5 with wild type CXCR4 and a previously identified WHIM syndrome Taken together, these studies identify a new WHIM syndrome mutant, CXCR4-S339fs5, that promotes enhanced

August 2022 "The X-linked form of Kallmann syndrome (KS), characterized by hypogonadotropic hypogonadism

of β-arrestin2 alleviates apoptosis through GRP78-ATF6-CHOP signaling pathway in primary Sjögren's syndrome The etiology of primary Sjögren's syndrome (pSS) remains unknown, and there is no ideal drug for the In this study, we established an experimental Sjögren's syndrome (ESS) mouse model to elucidate the molecular

However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical

However, until recently, most CB2 ligands were highly lipophilic and as such, not optimal for clinical

August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive

"We recently hosted our annual Scientific Advisory Board (SAB) summit at our site within Granta Park.

April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor positive

August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in transformative medicines for people living with psychiatric and neurological conditions, today announced positive KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (-21.2 KarXT vs. -11.6 placebo,

December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced positive

November 2021 Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive

However, blind assessments of ligand pose quality and affinity prediction have thus far not provided Median ligand RMSD values for top-scored poses were 1.2 Å and 2.0 Å for self-docking and StateMatch/FunctionMatch

Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors systematically aggregated somatic cancer mutations across class A GPCRs and found a nonrandom distribution of positions Individual cancer types were enriched for highly impactful, recurrent mutations at selected cognate positions drives this pattern, but rather multiple receptors contain amino acid substitutions at a few cognate positions GPCRs could moonlight as drivers or enablers of a given cancer through mutations located at cognate positions

teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST

Our findings suggest a positive feedback loop in which Wnt-stimulated local PI(4,5)P2 production enhances

October 2022 "Neisseria meningitidis is a Gram-negative opportunistic pathogen that is responsible for causing human diseases with high mortality, such as septicemia and meningitis. The molecular mechanisms N. meningitidis employ to manipulate the immune system, translocate the mucosal and blood-brain barriers, and exert virulence are largely unknown. Human-associated bacteria encode a variety of bioactive small molecules with growing evidence for N-acyl amides as being important signaling molecules. However, only a small fraction of these metabolites has been identified from the human microbiota thus far. Here, we heterologously expressed an N-acyltransferase encoded in the obligate human pathogen N. meningitidis and identified 30 N-acyl amides with representative members serving as agonists of the G-protein coupled receptor (GPCR) S1PR4. During this process, we also characterized two mammalian N-acyl amides derived from the bovine medium. Both groups of metabolites suppress anti-inflammatory interleukin-10 signaling in human macrophage cell types, but they also suppress the pro-inflammatory interleukin-17A+ population in TH 17-differentiated CD4+ T cells." Read more at the source #DrGPCR #GPCR #IndustryNews

Professor Deane is one of the UK’s most accomplished bioinformaticians. She has played an active role during the COVID-19 pandemic as the UKRI’s COVID Response Director, and

that other winners this year are the co-founders of BioNTech for their invention of the ( Pfizer ) Covid

NETosis and inflammatory response "Deep venous thrombosis (DVT) highly occurs in patients with severe COVID

and Clinical Management of the TADopathy, X-Linked Acrogigantism Thrombosis With Thrombocytopenia and Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic Plasma Exchange Chemistry July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs Post Doctoral Fellow Postdoc Position Principal Scientist, In vitro Pharmacology Senior Associate Scientist

Characterization of a novel positive allosteric modulator of the α1A-Adrenergic receptor. Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19. Deletion of macrophage Gpr101 disrupts their phenotype and function dysregulating host immune responses Identification of a potential structure-based GPCR drug for interstitial cystitis/bladder pain syndrome

Stay informed about the most recent developments in GPCR research and industry updates. targeting PAR-1 G protein-coupled receptors related to autoimmunity in postural orthostatic tachycardia syndrome Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner Monlunabant by Inversago Pharma for Metabolic Syndrome Basic and Clinical Pharmacology 2026 GPCR Jobs HIGHLIGHT Principal Scientist, In vitro pharmacology NEW Post-Doctoral Pharmacology Postdoctoral Scientist Senior Research Associate/Associate Scientist, Protein Science Post-Doctoral

Mutations in VLGR1 have been associated with the human Usher syndrome (USH), the most common form of

account the detrimental effect of mutations carried by distinct signalling proteins giving rise to syndromes